Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/24/2012WO2012068209A2 Bisthiazole inhibitors of pro-matrix metalloproteinase activation
05/24/2012WO2012068204A1 Fused heteroaryl inhibitors of pro-matrix metalloproteinase activation
05/24/2012WO2012068202A1 Novel monensin derivatives for the treatment and prevention of protozoal infections
05/24/2012WO2012068196A1 Bis heteroaryl inhibitors of pro-matrix metalloproteinase activation
05/24/2012WO2012068187A1 Poly(amide) polymers for the delivery of oligonucleotides
05/24/2012WO2012068169A2 Substance for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments
05/24/2012WO2012068161A1 Pyridazine derivatives, compositions and methods for treating cognitive impairment
05/24/2012WO2012068149A1 Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
05/24/2012WO2012068147A1 Controlled release mucoadhesive systems
05/24/2012WO2012068140A1 Nanoparticle isoflavone compositions & methods of making and using the same
05/24/2012WO2012068109A2 Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
05/24/2012WO2012068106A2 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
05/24/2012WO2012068096A2 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
05/24/2012WO2012068081A1 Intraesophageal administration of targeted nitroxide agents for protection against ionizing irradiation-induced esophagatis
05/24/2012WO2012068072A1 Use of cyanine dyes for the detection of tau for diagnosis of early-stage tauopathies
05/24/2012WO2012068067A1 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists
05/24/2012WO2012068041A1 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS
05/24/2012WO2012068038A2 Caffeic acid derivatives and their use in improving neuronal cell viability
05/24/2012WO2012068032A1 Fgfr1 extracellular domain combination therapies
05/24/2012WO2012067978A1 Antibacterial amiinoglycoside analogs
05/24/2012WO2012067970A2 Transcriptional repression leading to parkinson's disease
05/24/2012WO2012067965A1 Nampt and rock inhibitors
05/24/2012WO2012067963A1 Nampt inhibitors
05/24/2012WO2012067941A1 Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
05/24/2012WO2012067912A1 Local vascular delivery of adenosine a2a receptor agonists to reduce myocardial injury
05/24/2012WO2012067868A2 Coloring composition containing l-dopa and l-arginine and forming a non-covalent derivatization complex
05/24/2012WO2012067863A1 Heterocyclic compounds as imaging probes of tau pathology
05/24/2012WO2012067824A1 Potassium channel modulators
05/24/2012WO2012067822A1 Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
05/24/2012WO2012067670A1 Irinotecan immunoassay
05/24/2012WO2012067641A2 Methods and compositions for preventing and treating osteoarthritis
05/24/2012WO2012067614A1 Periodontitis treatment
05/24/2012WO2012067447A2 Composition containing styraxlignolide a or the aglycone thereof as an active ingredient for preventing or treating asthma
05/24/2012WO2012067322A1 Pharmaceutical composition for treatment of asthma containing 4-phenylbutyric acids or pharmaceutically acceptable salts thereof as active ingredient
05/24/2012WO2012067316A1 Composition for prevention or treatment of metabolic diseases or complications thereof containing pterocarpan-based compounds or pharmaceutically acceptable salts thereof as active ingredient, or composition for antioxidation
05/24/2012WO2012067305A1 COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING β-SECRETASE INHIBITOR
05/24/2012WO2012067269A1 Aminoalkoxyphenyl compounds and their use in the treatment of disease
05/24/2012WO2012067268A1 Cyclic amide compounds and their use in the treatment of disease
05/24/2012WO2012067224A1 Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders
05/24/2012WO2012067138A1 Novel polymer derivative of cytidine metabolism antagonist
05/24/2012WO2012067111A1 PKC-ε ACTIVATOR
05/24/2012WO2012066994A1 Pharmaceutical formulation having neuroprotective activity
05/24/2012WO2012066578A2 Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
05/24/2012WO2012066565A2 Asenapine maleate amorphous and crystalline form and process for preparation thereof
05/24/2012WO2012066546A1 Aminoglycosides and uses thereof in treating genetic disorders
05/24/2012WO2012066538A1 Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
05/24/2012WO2012066518A1 2-piperazin-1-yl-4h-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections
05/24/2012WO2012066508A1 Pharmaceutical combination of paclitaxel and a cdk inhibitor
05/24/2012WO2012066492A1 Processes for the preparation of carbapenem antibiotic composition
05/24/2012WO2012066486A1 Compound ethyl 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate, salt, crystalline form, cocrystal, formulation, processes for preparation, application as medicaments, pharmaceutical compositions and new use particularly as inhibitor of aurora kinases
05/24/2012WO2012066478A1 Quinolinone derivatives
05/24/2012WO2012066447A1 Compositions with antibacterial and wound healing activity
05/24/2012WO2012066442A1 Inhibitors of hiv replication
05/24/2012WO2012066401A1 Stable oral pharmaceutical compositions of montelukast
05/24/2012WO2012066366A1 New salts suitable for the preparation of pharmaceutical compositions
05/24/2012WO2012066347A1 Oil based formulations
05/24/2012WO2012066336A1 Benzylamine compounds as toll -like receptor 7 agonists
05/24/2012WO2012066335A1 Phenol compounds als toll -like receptor 7 agonists
05/24/2012WO2012066330A1 Compounds useful as a2a receptor inhibitors
05/24/2012WO2012066319A1 Apomorphine by pulmonary inhalation, oprionally in combination with l-dopa or a dopamine agonist for use in the treatment of parkinson
05/24/2012WO2012066257A1 Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
05/24/2012WO2012066256A1 Pharmaceutical composition comprising bicarbonate salt, and use thereof as a medicament in the treatment and/or prevention of urinary lithiasis and related diseases
05/24/2012WO2012066254A1 Pharmaceutical composition comprising krebs cycle precursor salt, in particular citrate salt, and use thereof as a medicament
05/24/2012WO2012066234A1 Novel indolizine derivatives, and preparation and therapeutic use thereof
05/24/2012WO2012066141A1 Markers for acute kidney injury and uses thereof
05/24/2012WO2012066095A1 Crystalline form of an inhibitor of mdm2/4 and p53 interaction
05/24/2012WO2012066092A1 Compounds for the modulation of aurora kinase a expression
05/24/2012WO2012066077A1 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
05/24/2012WO2012066070A1 3-(aminoaryl)-pyridine compounds
05/24/2012WO2012066065A1 Phenyl-heteroaryl amine compounds and their uses
05/24/2012WO2012066061A1 Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
05/24/2012WO2012066002A1 Flavagline derivatives as neuroprotective agents
05/24/2012WO2012065993A1 Vasoprotective and cardioprotective antidiabetic therapy
05/24/2012WO2012065967A1 Substituted sodium-1h-pyrazole-5-olate
05/24/2012WO2012065963A2 Novel antiviral compounds
05/24/2012WO2012065958A1 Method of treating contrast-induced nephropathy
05/24/2012WO2012065956A1 Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors
05/24/2012WO2012065953A1 Substituted carbamoylcycloalkyl acetic acid derivatives as nep inhibitors
05/24/2012WO2012065935A1 Methods of treating tumors
05/24/2012WO2012065755A1 Production of ifn-lambda by b cells
05/24/2012WO2012065740A1 Transdermal therapeutic system comprising buprenorphine
05/24/2012WO2012065612A1 Imidazole derivatives as pde10a enzyme inhibitors
05/24/2012WO2012065546A1 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
05/24/2012WO2012065527A1 Compouds and uses as l-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof
05/24/2012WO2012065384A1 Tromantadine compounds with adamantane structure, derivatives and analogs thereof, and their uses as anti-tumor pharmaceuticals
05/24/2012WO2012065383A1 Application of drug memantine with adamantane structure, derivatives and analogues thereof for preventing tumor indication
05/24/2012WO2012065297A1 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
05/24/2012WO2012065216A1 Signal transduction pathway modulation
05/24/2012WO2012047355A3 Subunit-selective nucleic acid inhibitors of glutamate receptors
05/24/2012WO2012045009A3 Polyphosphate and pyrophosphate derivative of saccharides
05/24/2012WO2012028963A3 Compositions including a sodium channel blocker (lamotrigine) and a b vitamin molecule (folate) for use in treating a psychological, a neurological, a neurodegenerative disorder, and a disorder involving pain
05/24/2012WO2012027247A3 Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
05/24/2012WO2012023024A3 Controlled release formulations of dronedarone
05/24/2012WO2012021800A3 Caspase inhibitors as therapeutics for neural and organ injury and imaging
05/24/2012WO2012021754A3 Bismuth-thiols as antiseptics for agricultural, industrial and other uses
05/24/2012WO2012021409A3 Anthraquinone Analogs
05/24/2012WO2012020989A3 Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof
05/24/2012WO2012018854A3 Pactamycin analogs and methods of use
05/24/2012WO2012018761A3 Method of treatment of androgen-mediated cancers
05/24/2012WO2012018759A3 Method of treatment of androgen-mediated cancers
1 ... 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 ... 7860